share_log

BMO Capital Initiates Coverage On IGM Biosciences With Outperform Rating, Announces Price Target of $21

BMO Capital Initiates Coverage On IGM Biosciences With Outperform Rating, Announces Price Target of $21

BMO资本开始对igm biosciences进行覆盖,评级为跑赢大盘,宣布价格目标为21美元。
Benzinga ·  2024/12/06 02:52  · 评级/大行评级

BMO Capital analyst Etzer Darout initiates coverage on IGM Biosciences (NASDAQ:IGMS) with a Outperform rating and announces Price Target of $21.

BMO Capital 分析师Etzer Darout对igm biosciences(纳斯达克:IGMS)启动了覆盖,给予了跑赢大盘的评级,并宣布了21美元的价格目标。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发